[go: up one dir, main page]

NO2008001I1 - Vildagliptin og farmasoytisk akseptable salter derav - Google Patents

Vildagliptin og farmasoytisk akseptable salter derav

Info

Publication number
NO2008001I1
NO2008001I1 NO2008001C NO2008001C NO2008001I1 NO 2008001 I1 NO2008001 I1 NO 2008001I1 NO 2008001 C NO2008001 C NO 2008001C NO 2008001 C NO2008001 C NO 2008001C NO 2008001 I1 NO2008001 I1 NO 2008001I1
Authority
NO
Norway
Prior art keywords
vildagliptin
pharmaceutically acceptable
acceptable salts
salts
pharmaceutically
Prior art date
Application number
NO2008001C
Other languages
English (en)
Other versions
NO2008001I2 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22777194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2008001(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2008001I1 publication Critical patent/NO2008001I1/no
Publication of NO2008001I2 publication Critical patent/NO2008001I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO2008001C 1998-12-10 2008-01-25 Vildagliptin og farmasoytisk akseptable salter derav NO2008001I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20906898A 1998-12-10 1998-12-10
PCT/EP1999/009708 WO2000034241A1 (en) 1998-12-10 1999-12-09 N-substituted 2-cyanopyrrolidines

Publications (2)

Publication Number Publication Date
NO2008001I1 true NO2008001I1 (no) 2008-02-18
NO2008001I2 NO2008001I2 (no) 2010-09-27

Family

ID=22777194

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20012853A NO318741B1 (no) 1998-12-10 2001-06-08 N-substituerte 2-cyanopyrrolidiner, farmasoytisk sammensetning som innbefatter slike, samt anvendelse derav for a hemme dipeptidyl-peptidase IV.
NO2008001C NO2008001I1 (no) 1998-12-10 2008-01-25 Vildagliptin og farmasoytisk akseptable salter derav
NO2008004C NO2008004I1 (no) 1998-12-10 2008-05-09 Kombinasjon omfattende vildagliptin eller et farmasoytisk akseptabelt salt derav, og metformin, eller et farmasoytisk akseptabelt salt derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20012853A NO318741B1 (no) 1998-12-10 2001-06-08 N-substituerte 2-cyanopyrrolidiner, farmasoytisk sammensetning som innbefatter slike, samt anvendelse derav for a hemme dipeptidyl-peptidase IV.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2008004C NO2008004I1 (no) 1998-12-10 2008-05-09 Kombinasjon omfattende vildagliptin eller et farmasoytisk akseptabelt salt derav, og metformin, eller et farmasoytisk akseptabelt salt derav

Country Status (34)

Country Link
US (1) US6166063A (no)
EP (1) EP1137635B1 (no)
JP (2) JP3681110B2 (no)
KR (2) KR20050047561A (no)
CN (1) CN1160330C (no)
AR (1) AR023719A1 (no)
AT (1) ATE307112T1 (no)
BR (1) BRPI9915985B8 (no)
CA (1) CA2350609C (no)
CO (1) CO5150173A1 (no)
CY (3) CY1105355T1 (no)
CZ (1) CZ299151B6 (no)
DE (3) DE69927844T2 (no)
DK (1) DK1137635T3 (no)
ES (1) ES2251847T3 (no)
FR (1) FR08C0005I2 (no)
HK (1) HK1040394B (no)
HU (1) HU226769B1 (no)
ID (1) ID28796A (no)
IL (2) IL143091A0 (no)
LU (2) LU91409I2 (no)
MY (1) MY123244A (no)
NL (2) NL300333I2 (no)
NO (3) NO318741B1 (no)
NZ (1) NZ511935A (no)
PE (1) PE20001317A1 (no)
PL (1) PL199443B1 (no)
RU (1) RU2251544C2 (no)
SK (1) SK286635B6 (no)
TR (1) TR200101478T2 (no)
TW (1) TW509674B (no)
UY (1) UY25843A1 (no)
WO (1) WO2000034241A1 (no)
ZA (1) ZA200104581B (no)

Families Citing this family (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US6852760B1 (en) * 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
DE19940130A1 (de) * 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
CA2393083C (en) * 1999-12-23 2010-01-26 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
US6380398B2 (en) 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
US20080076811A1 (en) * 2000-01-21 2008-03-27 Bork Balkan Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
CN1400908A (zh) * 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂的联合形式
AU2001228309A1 (en) * 2000-01-24 2001-08-07 Novo-Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
MXPA02012272A (es) 2000-07-04 2003-04-25 Novo Nordisk As Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
DE60134251D1 (de) 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
AU2001294197C1 (en) * 2000-10-06 2005-05-19 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
UA74023C2 (en) * 2000-11-10 2005-10-17 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
JP2005500308A (ja) 2001-06-20 2005-01-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病を治療するためのジペプチジルペプチダーゼ阻害剤
AU2002322344C1 (en) * 2001-06-27 2006-02-16 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
EP1399420B1 (en) 2001-06-27 2007-12-05 SmithKline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
ATE370943T1 (de) * 2001-06-27 2007-09-15 Smithkline Beecham Corp Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
US6709651B2 (en) * 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6861440B2 (en) 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
BR0213958A (pt) * 2001-10-31 2004-09-08 Novartis Ag Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
US20030135663A1 (en) * 2002-01-16 2003-07-17 Sun Microsystems, Inc. Method, system, and program for including device parameters from a device driver in a configuration file
WO2003068757A1 (en) 2002-02-13 2003-08-21 F. Hoffmann-La Roche Ag Novel pyridin- and pyrimidin-derivatives
CA2474460C (en) 2002-02-13 2009-12-22 F. Hoffmann-La Roche Ag Pyridine- and quinoline-derivatives
DE60304911D1 (de) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
US7307164B2 (en) * 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MXPA04012149A (es) * 2002-06-03 2005-04-19 Novartis Ag El uso de cianopirrolidinas sustituidas y prepraraciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas.
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
JP2004026678A (ja) * 2002-06-24 2004-01-29 Microbial Chem Res Found ２型糖尿病治療剤
AU2003248259A1 (en) * 2002-07-10 2004-02-02 Yamanouchi Pharmaceutical Co., Ltd. Novel azetidine derivative or salt thereof
EP1554256B1 (en) * 2002-07-15 2009-12-09 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200401635A (en) * 2002-07-23 2004-02-01 Yamanouchi Pharma Co Ltd 2-Cyano-4-fluoropyrrolidine derivative or salt thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BR0314582A (pt) * 2002-09-19 2005-08-09 Abbott Laboratoires Composições farmacêuticas como inibidoras da dipeptidil peptidase - iv (dpp-iv)
DE60315687T2 (de) 2002-10-07 2008-06-05 Merck & Co., Inc. Antidiabetische heterocyclische beta-aminoverbindungen als inhibitoren von dipeptidylpeptidase
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE60310991T2 (de) 2002-11-07 2007-10-18 Merck & Co, Inc. Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
CA2508487A1 (en) * 2002-12-04 2004-06-17 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1583534A4 (en) * 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2004065380A1 (en) 2003-01-14 2004-08-05 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
JP4564952B2 (ja) * 2003-01-17 2010-10-20 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
US7388019B2 (en) * 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
PE20050021A1 (es) * 2003-04-16 2005-03-15 Novartis Ag Procedimiento para la preparacion de 2-cianopirrolidina n-sustituida
GB0308854D0 (en) * 2003-04-16 2003-05-21 Novartis Ag Organic compounds
ATE447574T1 (de) * 2003-05-14 2009-11-15 Merck & Co Inc 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
AU2004247068A1 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2527806A1 (en) 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN100374439C (zh) 2003-06-20 2008-03-12 霍夫曼-拉罗奇有限公司 作为dpp-iv抑制剂的吡啶并‘2,1-a-异喹啉衍生物
ATE437876T1 (de) 2003-06-20 2009-08-15 Hoffmann La Roche Hexahydropyridoisochinoline als dpp-iv- inhibitoren
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1651623B1 (en) 2003-07-31 2008-12-17 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US20050070531A1 (en) 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
TW200530157A (en) * 2003-09-09 2005-09-16 Japan Tobacco Inc Dipeptidyl peptidase iv inhibitor
WO2005033099A2 (en) * 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
NZ546887A (en) * 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
CA2541212A1 (en) * 2003-11-04 2005-05-19 Wallace T. Ashton Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1743676A1 (en) * 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
EP1686994A2 (en) 2003-11-17 2006-08-09 Novartis AG Use of dipeptidyl peptidase iv inhibitors
PL1715893T3 (pl) * 2004-01-20 2010-03-31 Novartis Ag Preparat prasowany bezpośrednio oraz sposób
CN1918119B (zh) * 2004-02-05 2011-08-31 杏林制药株式会社 双环酯类衍生物
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005077900A1 (ja) * 2004-02-18 2005-08-25 Kyorin Pharmaceutical Co., Ltd. ビシクロアミド誘導体
WO2005079795A2 (en) * 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
EP1719757B1 (en) * 2004-02-27 2013-10-09 Kyorin Pharmaceutical Co., Ltd. Bicyclo derivative
CN1942186B (zh) * 2004-03-09 2010-10-06 国家卫生研究院 吡咯烷化合物
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102134229B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
TW200604167A (en) * 2004-04-27 2006-02-01 Astellas Pharma Inc Pyrrolidine derivatives
JP2007536234A (ja) 2004-05-04 2007-12-13 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての１，２，４−オキサジアゾール誘導体
CN1960990A (zh) * 2004-05-18 2007-05-09 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶－ⅳ抑制剂的环己基丙氨酸衍生物
US7935723B2 (en) * 2004-06-04 2011-05-03 Novartis Pharma Ag Use of organic compounds
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006012395A2 (en) 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
AR050615A1 (es) 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
NZ554515A (en) 2004-10-12 2009-12-24 Glenmark Pharmaceuticals Sa Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation
CN101035522B (zh) * 2004-10-25 2011-12-07 诺瓦提斯公司 Dpp-ⅳ抑制剂、ppar抗糖尿病剂和二甲双胍的组合
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005318597A1 (en) 2004-12-20 2006-06-29 F. Hoffmann-La Roche Ag 4-aminopiperidine derivatives
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
WO2006090244A1 (en) * 2005-02-22 2006-08-31 Glenmark Pharmaceuticals S.A. New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
TWI357902B (en) 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
EP1888562B1 (en) 2005-04-22 2014-06-18 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ATE550031T1 (de) 2005-06-06 2012-04-15 Univ Georgetown Zusammensetzungen und verfahren für die lipomodellierung
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US20090149504A1 (en) * 2005-06-17 2009-06-11 Aurigene Discovery Technologies Limited Novel 5-Substituted Indole Derivatives As Dipeptidyl Peptidase IV (DPP-IV) Inhibitors
EP1904058A2 (en) * 2005-07-12 2008-04-02 Novartis AG Combination of a dpp-iv inhibitor and a cannabinoid cb1 receptor antagonist
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
RU2008107873A (ru) * 2005-08-04 2009-09-10 Новартис АГ (CH) Новые соединения
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
JP2009510134A (ja) * 2005-10-07 2009-03-12 ワラタ ファーマシューティカルズ， インコーポレイテッド Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP2009522374A (ja) * 2006-01-06 2009-06-11 ノバルティス アクチエンゲゼルシャフト 糖尿病処置のためのビルダグリプチンの使用
WO2007102286A1 (ja) 2006-03-08 2007-09-13 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0709894A2 (pt) * 2006-04-03 2011-07-26 Matrix Lab Ltd inibidores de dipeptidil peptidase iv e processos para sua preparaÇço e composiÇço farmacÊuticas contendo-os
AU2007232311B2 (en) * 2006-04-03 2012-08-09 Mylan Laboratories Ltd Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
CN103323606A (zh) 2006-04-11 2013-09-25 艾尼纳制药公司 使用gpr119受体鉴定可用于增加个体骨质量的化合物的方法
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN109503584A (zh) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 多晶型
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
MY145447A (en) * 2006-09-13 2012-02-15 Takeda Pharmaceutical Use of 2-6(3-amino-piperidin-1-yl)-3-methyl-2, 4-dioxo-3, 4-dihydrp-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20080167479A1 (en) * 2007-01-10 2008-07-10 Medichem, S.A. Process for preparing vildagliptin
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
WO2008114857A1 (ja) 2007-03-22 2008-09-25 Kyorin Pharmaceutical Co., Ltd. アミノアセチルピロリジンカルボニトリル誘導体の製造方法
CA2682736C (en) 2007-04-03 2013-07-09 Mitsubishi Tanabe Pharma Corporation Combined use of dipeptidyl peptidase 4 inhibitor and sweetener
DE102007022007A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes
SI2152663T1 (sl) 2007-06-04 2014-08-29 Ben Gurion University Of The Negev Research And Development Authority Tri-arilne spojine in sestavki, ki vsebujejo isto
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
US8338450B2 (en) * 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
US20090082420A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched vildagliptin
WO2009042922A2 (en) * 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
RU2489439C2 (ru) * 2007-11-30 2013-08-10 Новартис Аг Органические соединения
KR20100098683A (ko) * 2007-12-12 2010-09-08 아스트라제네카 아베 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도
US8470836B2 (en) 2007-12-21 2013-06-25 Lg Life Sciences, Ltd. Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
PE20091730A1 (es) * 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
WO2009155309A1 (en) * 2008-06-19 2009-12-23 Concert Pharmaceuticals, Inc. Substituted cyanopyrrolidine derivatives
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
KR20110044780A (ko) * 2008-08-14 2011-04-29 교린 세이야꾸 가부시키 가이샤 안정화된 의약 조성물
CZ2008512A3 (cs) * 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
CN102850330B (zh) * 2008-09-23 2014-10-15 成都地奥制药集团有限公司 经溴代的制备n取代的吡咯烷衍生物的方法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN105384726A (zh) 2009-01-09 2016-03-09 幽兰化学医药有限公司 二肽基肽酶iv抑制剂
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
KR20160143897A (ko) 2009-02-13 2016-12-14 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
WO2010110436A1 (ja) 2009-03-27 2010-09-30 杏林製薬株式会社 塩基性添加剤を含有するマトリックス型徐放性製剤
EP2427445A1 (en) 2009-05-07 2012-03-14 AstraZeneca AB Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
AU2010247391A1 (en) 2009-05-15 2011-12-01 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
GB2483614B (en) 2009-06-18 2014-12-03 Lupin Ltd 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
EA034049B1 (ru) 2009-07-31 2019-12-23 КРКА, д.д., НОВО МЕСТО Гранулят, включающий вилдаглиптин, способ его получения и фармацевтическая композиция
CN102595897A (zh) 2009-09-02 2012-07-18 默沙东公司 作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃
CN102656163B (zh) 2009-09-03 2016-01-13 拜奥埃内杰尼克斯公司 抑制pask的杂环化合物
CA2774015A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
EP2295083A1 (de) 2009-09-15 2011-03-16 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin
HUP0900638A2 (en) 2009-10-07 2011-05-30 Egyt Gyogyszervegyeszeti Gyar Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions
IN2012DN02471A (no) 2009-10-09 2015-08-21 Irm Llc
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112012012210B8 (pt) 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
JP5686413B2 (ja) 2009-12-22 2015-03-18 塩野義製薬株式会社 アダマンタンアミン誘導体
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN101798270B (zh) * 2010-02-25 2013-04-17 东华大学 一种3-氨基-1-金刚烷醇的制备方法
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
EP2571876B1 (en) 2010-05-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
CN102260265B (zh) 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
CN101870671B (zh) * 2010-06-11 2012-06-27 漆又毛 金刚烷基吡咯烷衍生物及制备和应用
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
IT1400714B1 (it) 2010-07-06 2013-06-28 Chemelectiva S R L Processo ed intermedi per la preparazione di un principio attivo.
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI511958B (zh) * 2010-08-09 2015-12-11 Shionogi & Co 胺基金剛烷胺基甲酸酯衍生物之製造方法
HU231050B1 (hu) 2010-08-19 2020-02-28 Egis Gyógyszergyár Nyrt. Eljárás gyógyszerhatóanyag előállítására
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201010683A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San. Ve Ti̇c. A.Ş. Vildagliptin formülasyonları.
TR201101809A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
BR112013019352A2 (pt) 2011-01-31 2020-07-14 Cadila Healthcare Limited método para o tratamento de lipodistrofia, uso de um composto, dosagem diária, método de tratamento, composição farmacêutica, uso da composição farmacêutica e composto
BR112013022147A2 (pt) 2011-03-02 2017-04-25 Bioenergenix composto, composição farmacêutica, método de inibição da pask, método de tratamento de uma doença, método para alcançar um efeito em um paciente e método de tratamento de uma doença mediada pela pask
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
EP2753328A1 (en) 2011-09-07 2014-07-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dpp-iv inhibitor formulations
EP2572704A1 (en) 2011-09-22 2013-03-27 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-Disintegrating Formulations of Vildagliptin
PL2578208T3 (pl) 2011-10-06 2014-10-31 Sanovel Ilac Sanayi Ve Ticaret As Stałe formulacje dawkowane inhibitora DPP-IV
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
ITMI20112224A1 (it) 2011-12-06 2013-06-07 Chemelectiva S R L Nuovo processo ed intermedi per la sintesi di vildagliptin
CN102491928A (zh) * 2011-12-13 2012-06-13 临海天宇药业有限公司 一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法
US9115082B2 (en) 2012-01-18 2015-08-25 Catherine Yang Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
EP2814485A4 (en) 2012-02-17 2015-08-26 Merck Sharp & Dohme DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN102617434B (zh) * 2012-03-29 2014-07-23 中国科学院上海有机化学研究所 一锅法制备维达列汀
WO2013179300A2 (en) 2012-05-04 2013-12-05 Megafine Pharma (P) Ltd. A process for the preparation of vildagliptin and its intermediate thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9315508B2 (en) 2012-07-23 2016-04-19 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-IV inhibitors
WO2014020462A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of vildagliptin intermediate
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN103922986B (zh) * 2013-01-16 2017-02-15 上海彩迩文生化科技有限公司 维大列汀及其类似物、中间体及其制备方法和应用
AP2015008621A0 (en) 2013-02-14 2015-07-31 Novartis Ag Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors
US20160166539A1 (en) 2013-04-22 2016-06-16 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
CN103304502B (zh) * 2013-06-02 2015-03-04 张远强 一类抗糖尿病化合物、其制备方法和用途
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
IN2013MU02470A (no) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
CN105705167A (zh) 2013-07-25 2016-06-22 诺华股份有限公司 合成的apelin多肽的生物缀合物
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
EP3065723B1 (en) 2013-11-05 2020-09-23 Ben Gurion University of the Negev Research and Development Authority Compounds for the treatment of diabetes and disease complications arising from same
CN103641761A (zh) * 2013-11-22 2014-03-19 沈阳化工大学 一种维格利汀的制备方法
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EA201691793A1 (ru) 2014-03-06 2016-12-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Способ получения состава на основе вилдаглиптина в атмосфере инертного газа
CN103992257B (zh) * 2014-05-16 2016-03-30 苏州天马精细化学品股份有限公司 一种维格列汀粗品的纯化方法
CN105439873A (zh) * 2014-08-20 2016-03-30 天津药物研究院 3-羟基-1-金刚烷胺的制备方法
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CN105884669B (zh) * 2014-09-15 2020-05-15 深圳翰宇药业股份有限公司 制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CN104529857B (zh) * 2015-01-13 2016-03-30 佛山市赛维斯医药科技有限公司 卤代金刚烷酰胺类衍生物、其制备方法和用途
PE20171328A1 (es) 2015-01-23 2017-09-12 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media
KR20180006881A (ko) 2015-03-09 2018-01-19 인테크린 테라퓨틱스, 아이엔씨. 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
CN104761456B (zh) * 2015-03-10 2020-04-10 上海威智医药科技有限公司 3-氨基-1-金刚烷醇的制备方法
CN104817482B (zh) * 2015-03-17 2017-05-10 宁波百思佳医药科技有限公司 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
RU2628573C2 (ru) * 2015-11-27 2017-08-21 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа
KR20180092981A (ko) 2015-12-28 2018-08-20 욱크하르트 리미티드 빌다글립틴의 경구 삼투압성 약제학적 조성물
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
DE102016116130A1 (de) 2016-08-30 2018-03-01 Universität Bielefeld Verfahren zur Herstellung chiraler Aminonitrile
ES2946233T3 (es) 2016-09-16 2023-07-14 Galenicum Health S L U Composiciones farmacéuticas de vildagliptina
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
GR1009406B (el) 2017-10-03 2018-11-26 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
KR102622198B1 (ko) 2018-03-30 2024-01-09 한미약품 주식회사 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
GR1009644B (el) 2018-09-25 2019-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP2022507958A (ja) 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン／ケキシン９型（ｐｃｓｋ９）阻害薬としての環状四量体化合物
CN113166204B (zh) 2018-11-27 2025-01-28 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
JP7461735B2 (ja) * 2019-12-02 2024-04-04 日本ジェネリック株式会社 ビルダグリプチン含有錠剤
CN113527167B (zh) * 2020-04-14 2024-01-19 威智医药股份有限公司 一种维格列汀的生产方法
WO2021234430A1 (en) 2020-05-17 2021-11-25 Lotus International Pte. Ltd. Modified release dosage form comprising vildagliptin and process for manufacturing the same
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same
EP4192509A1 (en) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US20240174675A1 (en) * 2021-01-21 2024-05-30 The Scripps Research Institute Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
TW202333563A (zh) 2021-11-12 2023-09-01 瑞士商諾華公司 用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
US20240391941A1 (en) 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE296075C (no) *
DE158109C (no) *
FR2572399B1 (fr) * 1984-10-31 1987-01-16 Panmedica Sa Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
EP0419683A4 (en) * 1989-04-13 1992-03-11 Japan Tobacco Inc. New amino acid derivatives having prolylendopeptidase inhibitor activity
DE69124371T2 (de) * 1990-04-14 1997-06-12 New England Medical Center Inc Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
ATE349461T1 (de) * 1991-10-22 2007-01-15 New England Medical Center Inc Inhibitoren der dipeptidyl-aminopeptidase vom typ iv
PH31294A (en) * 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
FR2719049B1 (fr) * 1994-04-22 1996-06-14 Pasteur Institut Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules.
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
AU2790895A (en) * 1994-06-10 1996-01-05 Universitaire Instelling Antwerpen Purification of serine protease and synthetic inhibitors thereof
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6150587A (en) * 1997-06-27 2000-11-21 The Penn State Research Foundation Method and tissue culture media for inducing somatic embryogenesis, Agrobacterium-mediated transformation and efficient regeneration of cacao plants
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
JP2003190202A (ja) * 2001-12-28 2003-07-08 Yoshinobu Sekizawa 使い捨てカイロ目的別貼付位置及び禁止位置表示付き下着
US20050199741A1 (en) * 2002-06-08 2005-09-15 Thomson Ian R. Delivery system for a medicament or well-being enhancing composition

Also Published As

Publication number Publication date
JP2002531547A (ja) 2002-09-24
PE20001317A1 (es) 2000-12-13
ATE307112T1 (de) 2005-11-15
CY2008002I1 (el) 2009-11-04
NZ511935A (en) 2003-11-28
KR20050047561A (ko) 2005-05-20
EP1137635A1 (en) 2001-10-04
DE69927844D1 (de) 2006-03-02
HK1040394A1 (en) 2002-06-07
DK1137635T3 (da) 2006-02-13
NO20012853L (no) 2001-08-07
CY2008002I2 (el) 2009-11-04
AR023719A1 (es) 2002-09-04
IL143091A (en) 2006-07-05
JP3681110B2 (ja) 2005-08-10
EP1137635B1 (en) 2005-10-19
WO2000034241A1 (en) 2000-06-15
CA2350609C (en) 2008-09-02
ZA200104581B (en) 2002-05-22
CA2350609A1 (en) 2000-06-15
IL143091A0 (en) 2002-04-21
FR08C0005I2 (fr) 2009-01-15
LU91409I9 (no) 2019-01-02
AU1658000A (en) 2000-06-26
TR200101478T2 (tr) 2001-10-22
CO5150173A1 (es) 2002-04-29
NL300333I1 (nl) 2008-03-03
TW509674B (en) 2002-11-11
FR08C0005I1 (no) 2008-03-21
ID28796A (id) 2001-07-05
ES2251847T3 (es) 2006-05-01
CN1329593A (zh) 2002-01-02
HUP0104495A3 (en) 2002-11-28
NL300345I1 (nl) 2008-07-01
NO2008004I1 (no) 2008-06-02
SK286635B6 (sk) 2009-02-05
DE122008000007I1 (de) 2008-04-17
BRPI9915985B8 (pt) 2021-05-25
CY1105355T1 (el) 2010-03-03
PL348043A1 (en) 2002-05-06
NO2008001I2 (no) 2010-09-27
KR100509311B1 (ko) 2005-08-23
LU91409I2 (fr) 2008-03-17
US6166063A (en) 2000-12-26
UY25843A1 (es) 2001-08-27
HUP0104495A2 (hu) 2002-04-29
HK1040394B (zh) 2006-09-15
PL199443B1 (pl) 2008-09-30
LU91435I2 (fr) 2008-07-09
JP2005112864A (ja) 2005-04-28
NO318741B1 (no) 2005-05-02
CN1160330C (zh) 2004-08-04
NL300333I2 (nl) 2008-05-01
HU226769B1 (en) 2009-09-28
CZ20012028A3 (cs) 2001-09-12
RU2251544C2 (ru) 2005-05-10
KR20010080740A (ko) 2001-08-22
BR9915985A (pt) 2001-09-04
CY2008011I1 (el) 2012-01-25
SK7892001A3 (en) 2001-11-06
CZ299151B6 (cs) 2008-05-07
BR9915985B1 (pt) 2014-03-18
MY123244A (en) 2006-05-31
CY2008011I2 (el) 2012-01-25
DE122008000017I1 (de) 2008-08-07
NO20012853D0 (no) 2001-06-08
AU759773B2 (en) 2003-05-01
DE69927844T2 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
NO2008001I1 (no) Vildagliptin og farmasoytisk akseptable salter derav
NO2010006I1 (no) Saksagliptin og farmasytisk akseptable salter derav inklusive saksagliptin hydroklorid
NL300952I2 (nl) Peramivir en farmaceutisch aanvaardbare zouten daarvan
NO2011002I2 (no) Regadenoson og salter derav
NO2011021I2 (no) Apixaban og farmasøytiske akseptable salter derav
NO2006004I1 (no) Erlotinib hydroklorid og farmasoytisk akseptable salter derav
NO2008002I2 (no) Protiokonazol og salter derav
NO2013007I1 (no) Dapagliflozin og farmasøytisk akseptable salter derav
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
NO2005007I2 (no) Pemetrexed og farmasoytisk akseptable salter derav
NO20022086D0 (no) Antidiabetisk formulering og fremgangsmåte
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
EE200000438A (et) Farmatseutiliselt aktiivne morfolinool
IS2277B (is) Meðferðarlegar bíarýl afleiður
IL139030A0 (en) Therapeutic angiogenic factors and methods for their use
DE60028849D1 (de) Sterilisationsmethode
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
DK1637127T3 (da) Terapeutisk mikroskum
NO20015931D0 (no) Farmasöytiske formuleringer og fremgangsmåter som omfatter intranasal morfin
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
EP1187622A4 (en) STERILIZATION TECHNIQUE
HK1054031B (zh) 具有藥物活性的吡咯烷衍生物
DE69928344D1 (de) Pharmazeutisches Implantat
DE59812218D1 (de) Laterales Kieferimplantat
NO20010405L (no) Pyrazolderivater og salter derav

Legal Events

Date Code Title Description
MK1K Patent expired